Antibody Engineering for Lab Success DVD


 

Order DVDDVD Cover About the DVD: 

Biotherapeutic drug discovery programs present new and unique challenges for researchers, beyond those faced by traditional small molecule approaches. This collection of Introductory Antibody Engineering courses offers those new to the field or just getting started a foundation for future lab success. Covering topics spanning Discovery, Engineering and Optimization, these courses will feature real-life case studies, problems encountered and solutions applied, along with extensive coverage of the academic theory and background, to provide a basic understanding of the components of a successful antibody drug discovery program.

About the Conference: 

CHI U Training and Educational Services offers half day or full day intensive instructional courses at three levels: Introductory, Intermediate, and Advanced. Our course work is designed and taught by experienced trainers, who focus on content applicable to current research. These courses are designed for anyone from entry level to the senior executive who need a basic introduction or a place to brainstorm technical issues. Workshops incorporate lectures, interactive exercises and discussion groups with extensive Q&A.

Preview: 

 

About the DVD:
3 Presentations
101 Slides
Over 236 Minutes
Individual: $345
Site License: $1380

Agenda At A Glance: 

Engineering Optimized Biotherapeutics
Jonathan DavisJonathan H. Davis, Ph.D., Principal Scientist, Adnexus, a Bristol-Myers Squibb R&D Company
To successfully make it to market, a biotherapeutic needs optimization covering a wide range of characteristics, from potency and specificity to stability and low immunogenicity. This workshop will examine the various engineering approaches, help develop an idea of prioritization, and look at where in the discovery process each should be fit. Topics will include in silico methods for stabilization and deimmunization, selection technology for improving affinity, and design and formatting to achieve optimal drug-like properties.

Biography: Jonathan Davis received his Ph.D. from University of California, San Francisco, where he worked on protein structure and function. After a post-doc at Harvard Medical School studying RNA selection, structure, and function in the labs of Jack Szostak and Gerhard Wagner, he took a position in New Technologies at EMD-Lexigen (now EMD Serono) in Billerica. His work there involved improving antibody-based therapeutics, inventing a platform technology for generating heterodimeric Fcs as a basis for multifunctional molecules, and developing a novel scaffold based on an artificially-designed protein. He has extensive experience in selection technologies, library design, in silico modeling, and therapeutic discovery. In 2008 he moved to Adnexus, a Bristol-Myers Squibb R&D company, where he is a Principal Scientists in Protein Design, working on projects ranging from improving optimization protocols to development of novel biotherapeutics.

Engineering of Bispecific Antibodies
Raffi Tonikian, Ph.D., Scientist I, Protein Engineering, Biogen Idec
Current investigation of monoclonal antibody (mAb) combinations and discovery of next generation of therapeutics has renewed interest in strategies for dual-targeting to improve therapeutic efficacy. However, due to challenges with production, efforts directed toward the development of these molecules frequently highlight issues that hinder momentum to the clinic. The broad timeline between conception and bedside application of the molecules implies that the strategies for constructing therapeutic bispecific molecules may not follow the traditional approaches with mAbs.  This workshop is structured to provide a broad view of these molecules with a focus on the current obstacles and proposed alternatives that may push bispecifics to a faster discovery and development time.

Biography: Raffi Tonikian is a Scientist in the Department of Protein Engineering at Biogen Idec.  His work primarily involves selecting and screening antibody libraries for the discovery of antibody-based therapeutics for immune and neurobiological disorders.  He is also interested in structure-guided affinity maturation of antibodies isolated from natural or synthetic libraries.  Moreover, he is developing strategies for the isolation of antibodies from natural donors through immune repertoire sequencing using next-generation sequencing.  Raffi received his doctorate degree from the University of Toronto, where he used peptide phage display libraries to identify specificity profiles for signaling domains, which led to the mapping of large-scale protein interaction networks in several model organisms.  During that time, he also spent nearly two years at Genentech, Inc. as a Visiting Scientist in the Department of Protein Engineering.  Dr. Tonikian performed his postdoctoral work under the auspices of Dr. Sachdev Sidhu, where he developed and utilized phage-displayed libraries to isolate antibodies against cancer related antigens.  In addition, he worked on the development of antibody-DNA conjugates as biomarker detection reagents.

Discovery and Engineering of Therapeutic Antibodies
Chung-Ming HsiehChung-Ming Hsieh, Associate Director, Biologics, Abbott Bioresearch Center
Antibody discovery and engineering are integral and essential parts of an antibody drug discovery program.  This course will introduce a general work flow of an antibody project from preparation for its launch to having the drug candidates with an emphasis on selecting the proper discovery and engineering tools to achieve the intended goal. 

Biography: Dr. Hsieh currently holds an Associate Director position at the Abbott Bioresearch Center and is responsible for leading a team of scientists to generate and engineer Abbott’s therapeutic antibody candidates in multiple therapeutic areas in collaboration with discovery project teams.  Dr. Hsieh received the 2009 Donalee Tabern Outstanding Researcher from Abbott’s Volwiler Society in recognition of his contribution in establishing Abbott’s antibody generation platforms.  As a discovery project leader, Dr. Hsieh leads a separate team to develop dual-targeting biologics for autoimmune diseases.  Dr. Hsieh has contributed to more than 40 publications in peer-reviewed journals, and is listed as an inventor in multiple US patents and patent applications.  Prior to joining Abbott, Dr. Hsieh held a faculty position at the Harvard Medical School and Brigham and Women’s Hospital in Boston where he had previously completed his post-doctoral training.  Dr. Hsieh received his Doctor of Science from the Harvard School of Public Health in Biological Sciences and his Bachelor of Science from the National Taiwan University in Zoology.



By Series:
By Region:


Conference
& Course Catalog

CHI Catalog 


Short Course DVDs